Xeris Biopharma Holdings, Inc.
NASDAQ:XERSBiotechnology
+$0.04 today
- Market cap
- $3.10B
- Beta
- 0.90
- P/E (TTM)
- 98.7
- EPS (TTM)
- $0.07
Volume 2.76M
Average 1.66M
XERS Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Xeris Biopharma Holdings, Inc.NASDAQ: XERS
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development grows, but more slowly than its trailing trend
Q1 FY2026 research & development of $8.78M rose 13.3% year over year, behind the +26.3% change in trailing-twelve-month research & development. Sequentially, it rose 11.5% from the prior quarter. Over 3 fiscal years it compounded at +14.1% a year.
Context
- Research & development amounted to 10.7% of revenue in FY2025, down 1.9 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +13.3% toward the trailing-twelve-month pace of +26.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 31.17M USD
- Year-over-year change
- +21.9%
- 4-year CAGR
- +5.5%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 31.17M | +21.9% |
| FY2024 | 2024-12-31 | 25.56M | +14.4% |
| FY2023 | 2023-12-31 | 22.34M | +6.6% |
| FY2022 | 2022-12-31 | 20.97M | -16.7% |
| FY2021 | 2021-12-31 | 25.16M | — |
Research & Development vs competitors
How XERS compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +26.3% is the 6th highest of 9, against a peer median of +31.1%.
- Research & development amounts to 10.2% of revenue for XERS, versus a peer median of 22.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | €274.3M EUR | -10.0% | -9.3% | 22.7% | |
| LTM Jun 2026 | $253.86M USD | +1.2% | +24.8% | 30.6% | |
SEPNSepterna, Inc. | LTM Sep 2026 | $132.66M USD | +56.0% | — | 137.8% |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $101.27M USD | +35.7% | +54.7% | — |
| LTM Mar 2026 | $72.56M USD | +54.7% | +49.8% | 20.1% | |
| LTM Mar 2026 | $43.27M USD | +26.5% | +23.7% | — | |
| LTM Mar 2026 | $32.2M USD | +26.3% | +14.1% | 10.2% | |
| LTM Mar 2026 | $16.69M USD | -64.4% | -17.8% | — | |
| LTM Mar 2026 | $8.48M USD | +125.2% | +24.8% | 9.8% | |
| Peer median (excluding XERS) | — | +31.1% | +24.8% | 22.7% | |
Competitors are the stored peer set for XERS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 49.59M | 110.25M | 163.91M | 203.07M | 291.85M |
| Cost of Revenue | 13.32M | 22.63M | 28.65M | 36.83M | 53.41M |
| Gross Profit | 36.27M | 87.61M | 135.27M | 166.24M | 238.43M |
| Gross Margin | 73.1% | 79.5% | 82.5% | 81.9% | 81.7% |
| Research & Development | 25.16M | 20.97M | 22.34M | 25.56M | 31.17M |
| Selling, General & Admin | 125.72M | 137.75M | 146.1M | 163.48M | 182.37M |
| Operating Expenses | 151.43M | 169.55M | 179.28M | 199.88M | 213.54M |
| Depreciation & Amortization | 1.88M | 12.67M | 13.16M | 12.63M | 12.16M |
| EBITDA | (113.67M) | (69.31M) | (23.74M) | (13.99M) | 12.71M |
| EBITDA Margin | -229.2% | -62.9% | -14.5% | -6.9% | 4.4% |
| Operating Income | (115.16M) | (81.94M) | (44.01M) | (33.65M) | 24.9M |
| Operating Margin | -232.2% | -74.3% | -26.8% | -16.6% | 8.5% |
| Interest Income | 313K | 2.58M | 4.75M | 5.32M | 4.74M |
| Interest Expense | 7.18M | 14.1M | 26.61M | 33.18M | 29.08M |
| Other Income / Expenses | (7.57M) | (14.14M) | (19.49M) | (23.46M) | (24.34M) |
| Income Before Tax | (122.73M) | (96.08M) | (63.5M) | (57.1M) | 554K |
| Pre-Tax Margin | -247.5% | -87.2% | -38.7% | -28.1% | 0.2% |
| Income Tax Expense | 0 | (1.42M) | (1.25M) | (2.27M) | 0 |
| Net Income | (122.73M) | (94.66M) | (62.26M) | (54.84M) | 554K |
| Net Margin | -247.5% | -85.9% | -38.0% | -27.0% | 0.2% |
| EPS (Basic) | (1.55) | (0.70) | (0.45) | (0.37) | 0.00 |
| EPS (Diluted) | (1.55) | (0.70) | (0.45) | (0.37) | 0.00 |
| Weighted Avg Shares | 79.03M | 135.63M | 137.67M | 146.77M | 160.43M |
| Weighted Avg Shares (Diluted) | 79.03M | 135.63M | 137.67M | 146.77M | 172.74M |
Xeris Biopharma Holdings, Inc.
NASDAQ:XERS
Intrinsic Alpha fair value
Locked
Current Price
$16.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.